GMM Pfaudler shares locked in 10% lower circuit for second day in a row

Shares of the company have been witnessing selling as the promoters of the company have offered to sell shares at a significant discount.

Shares of GMM Pfaudler were locked in a 10 percent lower circuit for the second session in a row on BSE on September 23.

In the previous trading session, the stock hit 10 percent lower circuit of Rs 4,717 while today, it hit the lower circuit of Rs 4,245.30 in intraday trade on BSE.

The stock has been on a losing streak since September 16 and if it closes in the red today, it will be its sixth consecutive session of losses.

Shares of the company have been witnessing selling as the promoters of the company have offered to sell shares at a significant discount.

The company's promoters said they would sell nearly 26 lakh shares worth Rs 1,433 crore at a 33 percent discount (Rs 3,500) to Monday's market price of Rs 5,241.10 on BSE.

The promoters Pfaudler Inc. and Urmi Patel are selling 25.71 lakh shares or 17.59 percent of the total equity with an option to additionally sell 15.21 lakh shares that represent 10.41 percent of the total issued and paid-up equity share capital of the company, GMM Pfaudler said in a release.

The allocation shall be at or above the Floor Price on a price priority basis a multiple clearing price basis.

In a BSE filing on September 22, the company said it intended to exercise the oversubscription option to the extent of 4,28,571 (approximately 2.93 percent) equity shares of the company in addition to the base sale shares of 25,71,429 (approximately 17.59 percent) equity shares.

The final sale shares will be 30,00,000, constituting approximately 20.52 percent of the paid-up equity share capital of the company.

Mazhar Mohammad, Chief Strategist – Technical Research and Trading Advisory, Chartviewindia.in said that the stock may not hold strong support around Rs 4,000.

"If we go purely by technical charts then this counter has undergone a multi-week consolidation around Rs 3,950 before unleashing a sporadic upswing from the lows of Rs 4,000 to Rs 6,900 levels in just two weeks," Mohammad pointed out.

"In normal conditions, the chances of this level holding up will be much higher. However, considering the fact that this company has fixed OFS price at Rs 3,500, the strong support around Rs 4,000 may not hold," he added.

The analyst underscored that the next support on charts, below Rs 3,950, is placed around Rs 3,450 levels. Therefore, on bigger correction, it could become a buy around Rs 3,500 levels by default.

"Considering the strong interest and long term uptrend of this counter initial target in the zone of Rs 4,800 -Rs 5,200 can be expected over a period of time assuming it will bottom out around Rs 3,500 levels. If some are already holding then they should exit at the earliest opportunity," Mohammad said.

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

SD Solutions

Search This Blog